Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.58 |
| ▸ | CCR5 | P51681 | 2/20 | 0.58 |
| ▸ | CCR8 | P51685 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.44 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15045561 | 0.76 | CCR1 (0.62) | CCR1CCR5CCR8KDM4EPSMD14 | |
| SCHEMBL30492603 | 0.75 | CCR1 (1.00) | CCR1CCR5CCR8KDM4EPSMD14 | |
| SCHEMBL686948 | 0.75 | CCR1 (1.00) | CCR1CCR5CCR8KDM4EPSMD14 | |
| SCHEMBL15045470 | 0.75 | ALDH1A1 (0.46) | KDM4EGAAALDH1A1L3MBTL1MAPT | |
| SCHEMBL15045469 | 0.75 | NQO2 (0.41) | KDM4EGAAALDH1A1L3MBTL1MAPT | |
| SCHEMBL15045457 | 0.74 | CCR1 (0.50) | CCR1CCR5KDM4EGAAALDH1A1 | |
| SCHEMBL13338189 | 0.73 | CCR1 (0.69) | CCR1CCR5CCR8KDM4EPSMD14 | |
| SCHEMBL9041309 | 0.72 | CCR1 (0.67) | CCR1CCR5CCR8KDM4EPSMD14 | |
| SCHEMBL13561583 | 0.72 | ALDH1A1 (0.55) | KDM4EGAAALDH1A1L3MBTL1MAPT | |
| SCHEMBL17051649 | 0.72 | CCR1 (0.67) | CCR1CCR5CCR8KDM4EPSMD14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796705-B2 | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | SCHERING CORPORATION | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | HAVCR2, ELOC, ZC3HAV1 | CCR1 420/4885CCR5 465/4885CCR8 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.